Literature DB >> 20645101

Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature.

Sergio Siragusa1, William Morice, Morie A Gertz, Robert A Kyle, Philip R Greipp, John A Lust, Thomas E Witzig, Martha Q Lacy, Steven R Zeldenrust, S Vincent Rajkumar, Stephen J Russell, Suzanne R Hayman, Francis Buadi, Shaji K Kumar, David Dingli, Angela Dispenzieri.   

Abstract

The rate of asymptomatic amyloidosis (AL) among patients with newly diagnosed multiple myeloma (MM) or smoldering multiple myeloma (SMM) is unknown. We evaluated number and clinical significance of asymptomatic AL in consecutive MM and SMM patients, not having recognition of symptomatic AL at the time of their diagnostic bone marrow biopsy. Bone marrow biopsies were stained with Congo red and considered diagnostic for AL in case of positive Congo red staining with apple-green birefringence. Biopsies from 144 patients were evaluated: 77 had a diagnosis of MM and 67 of SMM. The median age was 59 (range 26-84) years; the median follow-up was 76 months (range 0-216). Immunoglobulin isotypes were 96/144 (67%), IgG; 23/144 (16%), IgA; 12/144 (8%), light chain only; 1/77 (1%), IgD; and biclonal or indeterminate, 12/144 (8%). Fifty-eight percent (84/144) were κ restricted. The presence of amyloid was found in two cases (1%, 95% CI -0.6 to 3.2), one in MM, and one in SMM group, and none had or developed signs or symptoms suggestive of organ involvement by amyloid. Among the 142 other patients without amyloid deposition in their index bone marrow, one (0.7%, 95% CI -0.6 to 2.0) developed symptomatic AL after 119 months.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20645101     DOI: 10.1007/s00277-010-1028-8

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  9 in total

1.  [A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].

Authors:  Y Liu; H Y You; L Z Yan; S Jin; J J Shang; X L Shi; S Yan; W Q Yao; D P Wu; W Liu; C C Fu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-04-14

2.  Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.

Authors:  Taxiarchis V Kourelis; Shaji K Kumar; Morie A Gertz; Martha Q Lacy; Francis K Buadi; Suzanne R Hayman; Steven Zeldenrust; Nelson Leung; Robert A Kyle; Stephen Russell; David Dingli; John A Lust; Yi Lin; Prashant Kapoor; S Vincent Rajkumar; Arleigh McCurdy; Angela Dispenzieri
Journal:  J Clin Oncol       Date:  2013-10-21       Impact factor: 44.544

3.  Clinical outcomes and prognostic factors in patients with multiple myeloma in South Tyrol: a retrospective single-center analysis.

Authors:  Maximilian Mair; Christian Straka; Thomas Buratti; Martina Tauber; Manfred Mitterer; Dominic Fong
Journal:  Ann Hematol       Date:  2020-03-05       Impact factor: 3.673

4.  Incidence and survival in non-hereditary amyloidosis in Sweden.

Authors:  Kari Hemminki; Xinjun Li; Asta Försti; Jan Sundquist; Kristina Sundquist
Journal:  BMC Public Health       Date:  2012-11-13       Impact factor: 3.295

Review 5.  Light chain (AL) amyloidosis: update on diagnosis and management.

Authors:  Michael Rosenzweig; Heather Landau
Journal:  J Hematol Oncol       Date:  2011-11-18       Impact factor: 17.388

6.  Stabilisation of Laryngeal AL Amyloidosis with Long Term Curcumin Therapy.

Authors:  Terry Golombick; Terrence H Diamond; Arumugam Manoharan; Rajeev Ramakrishna
Journal:  Case Rep Hematol       Date:  2015-06-25

7.  Anterior mediastinum invasion by multiple myeloma: A case report.

Authors:  Ying-Hui Xu; Lu-Guo Sun; Chao Sun; Ou Bai; Ting-Ting Liang; Ke-Wei Ma
Journal:  Oncol Lett       Date:  2017-02-22       Impact factor: 2.967

8.  The risk of renal disease is increased in lambda myeloma with bone marrow amyloid deposits.

Authors:  Piotr Kozlowski; Scott Montgomery; Rahel Befekadu; Victoria Hahn-Strömberg
Journal:  J Blood Med       Date:  2017-03-06

9.  Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study.

Authors:  Camille Tessier; Thomas Allard; Jean-Samuel Boudreault; Rayan Kaedbey; Vincent Éthier; Fléchère Fortin; Michel Pavic
Journal:  Curr Oncol       Date:  2021-05-26       Impact factor: 3.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.